125 related articles for article (PubMed ID: 17640305)
1. Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes.
Shimadoi S; Takami A; Kondo Y; Okumura H; Nakao S
Cancer Sci; 2007 Sep; 98(9):1368-72. PubMed ID: 17640305
[TBL] [Abstract][Full Text] [Related]
2. CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.
Kakinoki Y; Kubota H; Yamamoto Y
Int J Hematol; 2004 Jan; 79(1):55-62. PubMed ID: 14979480
[TBL] [Abstract][Full Text] [Related]
3. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
4. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J
J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742
[TBL] [Abstract][Full Text] [Related]
5. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
[TBL] [Abstract][Full Text] [Related]
7. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
Baldwin GC; Chung GY; Kaslander C; Esmail T; Reisfeld RA; Golde DW
Br J Haematol; 1993 Apr; 83(4):545-53. PubMed ID: 7686031
[TBL] [Abstract][Full Text] [Related]
8. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
9. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays.
Munn DH; Cheung NK
J Exp Med; 1989 Aug; 170(2):511-26. PubMed ID: 2526848
[TBL] [Abstract][Full Text] [Related]
10. Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity.
Mufson RA; Aghajanian J; Wong G; Woodhouse C; Morgan AC
Cell Immunol; 1989 Mar; 119(1):182-92. PubMed ID: 2646026
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.
Ragnhammar P; Frödin JE; Trotta PP; Mellstedt H
Cancer Immunol Immunother; 1994 Oct; 39(4):254-62. PubMed ID: 7525059
[TBL] [Abstract][Full Text] [Related]
13. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
[TBL] [Abstract][Full Text] [Related]
14. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
Qi CF; Nieroda C; De Filippi R; Greiner JW; Correale P; Schlom J; Tsang KY
Immunol Lett; 1995; 47(1-2):15-24. PubMed ID: 8537095
[TBL] [Abstract][Full Text] [Related]
15. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor (G-CSF) could enhance Fcgamma receptor expression in neutrophils of patients with B-cell lymphoma treated with rituximab.
Sashida G; Takaku TI; Honda S; Ishii Y; Yamaguchi N; Sumi M; Shoji N; Gotoh A; Shimamoto T; Ito Y; Ohyashiki K
Leuk Lymphoma; 2005 May; 46(5):789-91. PubMed ID: 16019521
[No Abstract] [Full Text] [Related]
17. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity.
Young DA; Lowe LD; Clark SC
J Immunol; 1990 Jul; 145(2):607-15. PubMed ID: 2142182
[TBL] [Abstract][Full Text] [Related]
18. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 2 and 4 surface expressions on human monocytes are modulated by interferon-gamma and macrophage colony-stimulating factor.
Mita Y; Dobashi K; Shimizu Y; Nakazawa T; Mori M
Immunol Lett; 2001 Sep; 78(2):97-101. PubMed ID: 11672593
[TBL] [Abstract][Full Text] [Related]
20. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
